AbbVie has agreed to acquire Gilgamesh Pharmaceuticals’ lead asset, bretisilocin (GM-2505), a potential best-in-class compound for the treatment of major depressive disorder (MDD), for up to $1.2 billion. Psychedelic compounds have gained recognition as potential treatments for mental health disorders, because of their demonstrated rapid, robust and durable antidepressant effects. Bretisilocin, a 5-HT2A receptor agonist […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!